Xiaoxuan Li, Huiyan Wang, Wujiang Lai, Jinrong Liao, Wenyu Mo, Keke Huang, Liqing He, Xiaomei Liang, Zhibin Yu, Jiang Xu, Xianwu Hua, Fujun Hou, Jun Ding, William Wei-Guo Jia, Kuan Zhang, Yifeng Wang (2024).
Zahid Delwar, Olga Tatsiy, Dmitry V. Chouljenko, I-Fang Lee, Guoyu Liu, Xiaohu Liu, Luke Bu, Jun Ding, Manu Singh, Yanal M Murad, William Wei-Guo Jia * (2023).
The oncolytic virus therapy VG161 was well tolerated and showed encouraging antitumour activity, including improved overall survival versus second-line FOLFOX chemotherapy, even though most patients received VG161 as third-line or later therapy.(2025).
Yinan Shen, Xueli Bai, Qi Zhang, Xingmei Liang, Xinyan Jin, Zeda Zhao, Wei Song, Qian Tan, Ronghua Zhao, William Jia, Shanzhi Gu, Guoming Shi, Ziwei Zheng, Guyue Wei, Youlei Wang, Tian Fang, Yuwei Li, Zijun Wang, Zifan Yang, Sida Guo, Danni Lin, Fang Wei, Lei Wang, Xiaoli Sun, …Tingbo Liang (2025).
Fu, S., Kundranda, M. N., Rahimian, S., Shen, Y., Tan, Q., Zhao, R., Esmaeili, N., Singh, M., Ding, J., Murad, Y., & Liang, T. (2023).
For more information, please visit our Publication Archive.
